Recent Updates
Recently added Catalysts
AMGN

Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday, Sept. 17, 2021. Peter...

Key Takeaway: THOUSAND OAKS, Calif. , Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday , Sept. 17, 2021. Peter H. Griffith , executive vice president and chief financial officer at Amg
Price reaction · baseline $213.75 (2021-09-10 close) · 2 other AMGN headline(s) in the window, move may be shared
day 0 close
+1.4%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Maridebart cafraglutide
Phase 3 · Heart Failure With Preserved Ejection Fraction

Full Press Release Details

THOUSAND OAKS, Calif. , Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday , Sept. 17, 2021. Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for seven days after the event.
About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Last updated: Sep 13, 2021